article Open AccessTop 1% cited
An inflammatory cytokine signature predicts COVID-19 severity and survival
Nature Medicine · 2020 · Vol. 26(10) · pp. 1636–1643
Diane M. Del Valle✉(Icahn School of Medicine at Mount Sinai)Seunghee Kim‐Schulze(Icahn School of Medicine at Mount Sinai)Hsin-Hui Huang(Icahn School of Medicine at Mount Sinai)Noam D. Beckmann(Icahn School of Medicine at Mount Sinai)Sharon Nirenberg(Icahn School of Medicine at Mount Sinai)Bo Wang(Icahn School of Medicine at Mount Sinai)Yonit Lavin(Icahn School of Medicine at Mount Sinai)Talia H. Swartz(Icahn School of Medicine at Mount Sinai)Deepu Madduri(Icahn School of Medicine at Mount Sinai)Aryeh Stock(Icahn School of Medicine at Mount Sinai)Thomas U. Marron(Icahn School of Medicine at Mount Sinai)Hui Xie(Icahn School of Medicine at Mount Sinai)Manishkumar Patel(Icahn School of Medicine at Mount Sinai)Kevin Tuballes(Icahn School of Medicine at Mount Sinai)Oliver Van Oekelen(Icahn School of Medicine at Mount Sinai)Adeeb Rahman(Icahn School of Medicine at Mount Sinai)Patricia Kovatch(Icahn School of Medicine at Mount Sinai)Judith A. Aberg(Icahn School of Medicine at Mount Sinai)Eric E. Schadt(Icahn School of Medicine at Mount Sinai)Sundar Jagannath(Icahn School of Medicine at Mount Sinai)Madhu Mazumdar(Icahn School of Medicine at Mount Sinai)Alexander W. Charney(Icahn School of Medicine at Mount Sinai)Adolfo Firpo‐Betancourt(Icahn School of Medicine at Mount Sinai)Damodara Rao Mendu(Icahn School of Medicine at Mount Sinai)Jeffrey S. Jhang(Icahn School of Medicine at Mount Sinai)David L. Reich(Icahn School of Medicine at Mount Sinai)Keith Sigel(Icahn School of Medicine at Mount Sinai)Carlos Cordon‐Cardo(Icahn School of Medicine at Mount Sinai)Marc Feldmann(University of Oxford)Samir Parekh(Icahn School of Medicine at Mount Sinai)Miriam Mérad(Icahn School of Medicine at Mount Sinai)Sacha Gnjatic(Tisch Hospital)
COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19SARS-CoV-2 and COVID-19 ResearchMedicineInternal medicineDiseaseCytokineTumor necrosis factor alphaCohortProspective cohort studySeverity of illnessImmunologyCohort study
MeSH terms
BetacoronavirusCOVID-19SARS-CoV-2AgedFemaleHospitalizationHumansMaleMiddle AgedPneumonia, ViralSeverity of Illness IndexTumor Necrosis Factor-alphaInterleukin-6Survival RateCytokines
Funding
- Gilead Sciences
- National Institutes of Health
- National Cancer Institute
Citations
2,683
FWCI
52.39
field-weighted impact
References
36
Percentile
100%
vs. same field & year
Citations per year
Cited by
Immunology of COVID-19: Current State of the Science
Immunity · 2020 · 1,775 citations
Risk factors for severe and critically ill COVID‐19 patients: A review
Allergy · 2020 · 1,439 citations
References
A note on competing risks in survival data analysis
British Journal of Cancer · 2004 · 744 citations
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Science Translational Medicine · 2014 · 2,472 citations
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Nature Reviews Drug Discovery · 2012 · 1,731 citations
Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.
Journal of Clinical Investigation · 1989 · 1,987 citations
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
Intensive Care Medicine · 2020 · 5,148 citations
COVID-19: consider cytokine storm syndromes and immunosuppression
The Lancet · 2020 · 10,120 citations
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
JAMA · 2020 · 9,847 citations
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages
Nature reviews. Immunology · 2020 · 2,572 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
